- Press Release
- Spinal Cord Injury Therapeutics Market to Surpass US$ 9,239.1 Million by 2027
Spinal Cord Injury Therapeutics Market to Surpass US$ 9,239.1 Million by 2027 - Coherent Market Insights
Published On : Dec 18, 2020
Global Spinal Cord Injury Therapeutics Market, by Injury Type (Complete Spinal Cord Injury and Incomplete Spinal Cord Injury), by Drug Type (Corticosteroids, Muscle Relaxants and Anti-spastic drugs, Non-steroidal Anti-inflammatory drugs ( NSAID’S), Anti-depressants, Anticonvulsants, and Others), by Application (Autonomic Dysreflexia (AD), Spasticity & Inflammation, Pain Management, and Depression), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 6,630.7 million in 2020 and is expected to exhibit a CAGR of 6.7% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Rising government investments in key companies to promote research and development for treatment of spinal cord injuries is expected to drive the global spinal cord injury therapeutics market. For instance, in 2018, BioAxone BioSciences, Inc. announced that they received two-year grant of US$ 1.1 Million, which provides funding for further development of BioAxone's preclinical candidate BA-434, a novel sd-rxRNA compound that targets phosphatase and tensin homolog (PTEN) for the treatment of spinal cord injury (SCI). The funding was granted from the National Institute of Neurological Disorders and Stroke (NINDS), a part of the U.S. National Institutes of Health.
Global Spinal Cord Injury Therapeutics Market – Impact of Coronavirus (COVID-19)
Browse 33 Market Data Tables and 32 Figures spread through 175 Pages and in-depth TOC on “Global Spinal Cord Injury Therapeutics Market, by Injury Type (Complete Spinal Cord Injury and Incomplete Spinal Cord Injury), by Drug Type (Corticosteroids, Muscle Relaxants and Anti-spastic drugs, Non-steroidal Anti-inflammatory drugs ( NSAID’S), Anti-depressants, Anticonvulsants, and Others), by Application ( Autonomic Dysreflexia (AD), Spasticity & Inflammation, Pain Management, and Depression), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”
To know the latest trends and insights prevalent in the global spinal cord injury therapeutics market, click the link below:
https://www.coherentmarketinsights.com/market-insight/spinal-cord-injury-therapeutics-market-4305
The market is expected to witness significant growth during the forecast period, owing to key players focusing on research and development for the treatment of spinal cord injury. For instance, in 2019, BioArctic AB, a Sweden-based research-based biopharmaceutical company, announced that they are currently in phase 2 clinical trial of investigation study on treatment of spinal cord injury with its product candidate SC0806 and also stated that they have initiated enrolling of subjects to study the efficacy and safety of product.
Key Takeaways of the Global Spinal Cord Injury Therapeutics Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.